-
1Academic Journal
المؤلفون: E. Ulupova O., G. Bogdanova A., T. Karonova L., E. Grineva N., Е. Улупова О., Г. Богданова А., Т. Каронова Л., Е. Гринева Н.
المصدر: Translational Medicine; Том 5, № 3 (2018); 28-35 ; Трансляционная медицина; Том 5, № 3 (2018); 28-35 ; 2410-5155 ; 2311-4495 ; 10.18705/2311-4495-2018-5-3
مصطلحات موضوعية: amiodarone-induced thyrotoxicosis, FТ3, FТ4, FТ4/FТ3 ratio, амиодарон-индуцированный тиреотоксикоз, св.Т3, св.Т4, соотношение св.Т4/Т3
وصف الملف: application/pdf
Relation: https://transmed.almazovcentre.ru/jour/article/view/435/309; Martino E, Bartalena L, Bogazzi F, Braverman LE. The Effects of Amiodarone on the Thyroid. Endocrine Reviews. 2001; 22: 240 — 254.; Bogazzi F, Bartalena L, Gasperi M. et al. The Various Effects of Amiodarone on Thyroid Function Thyroid. 2001; 11: 511-519.; Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function Nat. Rev. Endocrinol.2009; 6:34–41.; Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Practice Research Clinical Endocrinology Metabolism. 2009; 23:735–751.; Гринева Е.Н, Дора С.В, Малахова Т.В, Малахова З.Л. Влияние амиодарона на структуру и функцию щитовидной железы. Проблемы эндокринологии. 2008; 54: 17-21.; Гринева Е.Н., Бабенко А.Ю., Выговский А.Б. Кордарон-индуцированный тиреотоксикоз: трудности диагностики и врачебной тактики. Проблемы эндокринологии. 2005; 51(4): 18.; Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005;118: 706-714.; Bogazzi F, Bartalena L, Martino E. Approach to the Patient with Amiodarone-Induced Thyrotoxicosis. JCEM. 2010; 95: 2529–2535.; Pattison DA, Westcott J, Lichtenstein M, et al: Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nuclear Medicine Communications. 2015; 36: 356–362.; Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Can J Cardiol. 2009; 25: 421-424.; Bogazzi F, Martino E, Dell’Unto E, et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis J. Endocrinol. Invest. 2003; 26: 635-640.; Eaton SEM, Euinton HA, Newman CM, et al. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography Clinical Endocrinology. 2002; 56: 33–38.; Barvalia U, Amlani B, Pathak R. Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge. Hindawi Publishing Corporation Case Reports in Medicine Volume. 2014; Article ID 231651, 1-6.; Tanda ML, Piantanida E, Lai A, et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf). 2008; 69:812 — 818.; Sriphrapradang C, Bhasipol A. Differentiating Graves’ disease from subacute thyroiditis using ratio of serum free triiodothyronine to free thyroxine. Annals of Medicine and Surgery. 2016; 10: 69-72.; Yoshimura Noh J, Momotani N, Fukada S, et al. Ratio of serum free triiodothyronine to free thyroxine in Graves’ hyperthyroidism and thyrotoxicosis caused by painless thyroiditis, Endocr. J. 2005; 52: 537-542.; Yanagisawa T, Sato K, Kato Y. et al. Rapid differential diagnosis of Graves’ disease and painless thyroiditis using total T3/T4 ratio, TSH, and total alkaline phosphatase activity. Endocr J. 2005; 52:29-36.; Bogazzi F, Bartalena L, Brogioni S. et al. Color flow Doppler sonography rapidly differentiates typeI and type II amiodarone-induced thyrotoxicosis. Thyroid. 1997; 7: 541545.; Bogazzi F, Bartalena L, Dell’Unto E. et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clinical Endocrinology. 2007; 67: 533–537.; Carle ́ A, Knudsen N, Bu ̈low Pedersen I, et al. Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study. Eur JEndocrinol. 2013; 169: 537–545.; Martino E, Safran M, Aghini-Lombardi F. et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med. 1984; 101:28 — 34.; Sidhu, J, Jenkins D. Men are at increased risk of amiodarone-associated thyrotoxicosis in the UK. QJM. 2003; 96: 949–950.; Amino N, Yabu Y, Miki T. et al. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves’ disease and destruction-induced thyrotoxicosis. JCEM. 1981; 53: 113–116.; Laurberg P. Mechanisms Governing the Relative Proportions of Thyroxine and 3,5,3’-Triiodothyronine in Thyroid Secretion Metabolism. 1984; 33: 379-392.; Laurberg P, Vestergaard H, Nielsen S. et al. Sources of Circulating 3,5,3`-Triiodothyronine in Hyperthyroidism Estimated after Blocking of Type 1 and Type 2 Iodothyronine Deiodinases. JCEM. 2007; 92: 2149 –2156.; Salvatore D, Tu H, Harney JW, Larsen R. Type 2 Iodothyronine Deiodinase Is Highly Expressed in Human Thyroid J. Clin. Invest. 1996; 98:962–968.; Murakami M, Araki O, Hosoi Y. et al. Expression and Regulation of Type II Iodothyronine Deiodinase in Human Thyroid Gland. Endocrinol. 2001; 142: 2961- 2967.; Nelson JC, Wang R, Asher DT, Wilcox RB. Underestimates and overestimates of total thyroxine concentrations caused by unwanted thyroxine-binding protein effects. Thyroid. 2005; 15: 12–15.; Shigemasa C, Abe K, Taniguchi S. et al. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves’ disease despite similar serum total T4 levels. JCEM. 1987; 65: 359–363.; Izumi Y, Hidaka Y, Tada H. et al. Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves’ thyrotoxicosis. Clin Endocrinol (Oxf). 2002; 57: 51–58.; https://transmed.almazovcentre.ru/jour/article/view/435